Clene Inc. CLNN

Clene Inc. closed a $4 million registered direct offering of common stock to existing shareholders, including insiders. The sale, led by Chairman David Matlin with Kensington Capital Holdings and Clene’s CEO, was priced at market under Nasdaq rules and conducted without a placement agent. Proceeds are expected to fund operations into mid‑Q1 2027, extending the cash runway beyond the FDA’s potential decision on whether to accept Clene’s CNM-Au8 NDA for accelerated approval in ALS. If the FDA accepts the NDA, warrants issued in a January 2026 financing could add another $6.7 million to $7.8 million in proceeds, further extending liquidity. Clene is a late-stage biotech focused on mitochondrial health and neurodegenerative diseases; CNM-Au8 is an investigational therapy targeting ALS. Extends cash runway into mid-2027 and ties potential additional funds to FDA NDA review, improving financial outlook amid regulatory uncertainty.

Clene plans Q4 NDA submission for ALS drug after completing FDA-requested biomarker analyses. NDA filing for ALS drug marks major regulatory milestone that can shift company trajectory and investor sentiment.

Clene Inc. (CLNN) released second quarter 2026 financial results and recent operating highlights. Quarterly financial results and operating updates deliver moderate updates on company performance and pipeline progress.

Clene Inc. (CLNN) reported a loss for Q2, falling short of revenue estimates. The company's financial performance has raised concerns among investors as it continues to struggle with its revenue generation. The results indicate challenges in meeting market expectations, which may impact investor sentiment moving forward. The missed revenue estimates suggest a moderately noticeable influence on Clene Inc.'s financial performance and market perception.

Clene Inc. reported its financial results for the second quarter of 2025, highlighting key operational achievements and financial metrics. The company continues to advance its clinical programs and maintain a strong cash position, which supports ongoing research and development efforts. Management expressed optimism about future growth and the potential impact of their innovative therapies on patient outcomes. The financial results and operational highlights indicate moderate progress that may influence Clene's market position and investor sentiment.

Clene targets early Q4 NDA filing for CNM-Au8 in ALS. NDA filing for CNM-Au8 in ALS marks major regulatory step that can drive substantial valuation changes and commercial prospects.

Clene Inc. (CLNN) reported first quarter 2026 financial results and recent operating highlights. Quarterly financial results and operating highlights affect financial performance and investor sentiment but are routine updates.

Clene Inc. CEO stated at a conference that FDA meeting minutes suggest CNM-Au8 clinical data could support a New Drug Application filing for ALS treatment. Positive FDA feedback on CNM-Au8 data signals potential ALS NDA filing, a major regulatory step that could significantly boost Clene's market position and investor sentiment.

Clene Inc. (CLNN) plans to file an Accelerated Approval NDA for its ALS treatment after a successful FDA meeting. Filing for accelerated FDA approval for ALS drug after successful meeting positions Clene for potential market transformation.

Clene Inc. (CLNN) reported full year 2025 financial results and recent operating highlights. Full-year financial results and operating highlights represent major updates that could significantly influence investor sentiment and company trajectory.

Clene Inc. (CLNN) announces FDA regulatory path for ALS drug CNM-Au8, highlights key biomarkers supporting efficacy, and extends cash runway into 2025. FDA pathway for ALS drug CNM-Au8 with biomarkers and extended cash runway enable major clinical advancement and financial stability.

Clene Inc. issued a stockholder letter highlighting key 2026 catalysts for CNM-Au8®, including potential regulatory submissions and commercialization milestones for ALS and MS treatments. Highlighting 2026 catalysts for CNM-Au8® signals major pipeline advancements that could reshape Clene's competitive position and drive substantial stock performance.

Clene Inc. announced that the FDA has granted a Type C meeting regarding its ALS treatment, CNM-Au8, as the company aims for accelerated approval in the second quarter. This meeting is a critical step in the regulatory process, potentially expediting the availability of the treatment for patients. The FDA's Type C meeting indicates significant regulatory engagement that could influence the approval timeline and market positioning of CNM-Au8.

Clene Inc. will present at the Emerging Growth Conference, showcasing its innovative therapies and business strategies to potential investors and stakeholders. The conference aims to connect emerging growth companies with investors, providing a platform for Clene to highlight its advancements and future plans. Participation in the conference may enhance investor interest and visibility, but the overall impact on the company's trajectory is expected to be limited.

Clene Inc. announced additional biomarker data for its CNM-Au8 treatment, which supports the potential filing of a New Drug Application (NDA). This data will be presented at an upcoming in-person meeting with the FDA, indicating progress in the regulatory process for the treatment aimed at neurodegenerative diseases. The new biomarker data and potential NDA filing could significantly influence Clene's regulatory approval process and market position.

Clene Inc. announced a registered direct offering of over $28 million, aimed at raising capital to support its operations and development initiatives. The offering is expected to enhance the company's financial position and facilitate its growth strategy. Details regarding the pricing and terms of the offering were not disclosed, but the move reflects Clene's ongoing efforts to secure funding for its projects. The capital raise may provide necessary funding for operations and growth, but its overall impact on the company's trajectory remains limited.

Clene Inc. will present at the Emerging Growth Conference, showcasing its innovative therapies and business strategies to potential investors and stakeholders. The conference aims to connect emerging growth companies with investors, providing a platform for Clene to highlight its advancements and future plans. Participation in the conference may enhance investor awareness and sentiment, but the overall impact on Clene's trajectory is expected to be limited.

Clene Inc. announced statistically significant biomarker results for its drug CNM-Au8®, which supports an accelerated approval pathway for treating amyotrophic lateral sclerosis (ALS). These findings are expected to enhance the company's position in the ALS market and potentially expedite the regulatory process for the drug's approval. The positive biomarker results could significantly influence Clene's regulatory trajectory and market positioning in ALS treatment.

Clene Inc. announced an update on its CNM-Au8® program for amyotrophic lateral sclerosis (ALS), highlighting progress in clinical trials and ongoing research efforts. The company aims to advance its treatment options for ALS patients and improve outcomes through innovative therapies. Details regarding trial results and future plans were shared, emphasizing Clene's commitment to addressing this challenging condition. The update on the CNM-Au8® program indicates significant advancements that could enhance Clene's market position and investor sentiment.

Clene Inc. (CLNN) reported a loss for Q3, falling short of revenue estimates. The company's financial performance has raised concerns among investors, as it continues to struggle in meeting market expectations. Analysts are closely monitoring the situation to assess potential impacts on future operations and growth. The revenue miss and reported loss may moderately influence investor sentiment and financial performance.

Clene Inc. reported its financial results for the third quarter of 2025, highlighting key operational achievements and financial metrics. The company continues to focus on its innovative therapies and strategic initiatives aimed at enhancing its market position. Management provided insights into future growth prospects and ongoing projects, emphasizing their commitment to advancing clinical development and expanding their product pipeline. The financial results and operational highlights indicate a moderate influence on Clene's performance and market sentiment.

Clene Inc. will present at the Emerging Growth Conference, showcasing its innovative therapies and business strategies to potential investors and stakeholders. The event aims to enhance visibility and engagement with the investment community, highlighting Clene's commitment to advancing its clinical programs and growth initiatives. Participation in the conference may enhance investor interest and visibility, but the overall impact on the company's trajectory is expected to be limited.

Clene Inc. presented new clinical data at the ECTRIMS 2025 meeting, showcasing that CNM-Au8® significantly improves brain energy metabolism in patients with multiple sclerosis. The findings suggest potential therapeutic benefits of CNM-Au8® in enhancing brain function and energy levels, which could lead to improved patient outcomes in this population. The presentation of new clinical data indicating significant improvements in brain energy metabolism could lead to increased interest and investment in Clene's therapeutic offerings.

Clene Inc. presented preclinical data supporting the use of CNM-Au8® for treating Parkinson’s Disease. The findings suggest that CNM-Au8® may enhance neuronal function and reduce neuroinflammation, potentially offering a new therapeutic approach for patients. This data is part of Clene's ongoing research efforts to develop innovative treatments for neurodegenerative diseases. The preclinical data could significantly influence Clene's product development and market positioning in the treatment of Parkinson's Disease.

Clene Inc. will present at the H.C. Wainwright 27th Annual Global Investment Conference, showcasing its advancements and strategies to potential investors. The conference is a significant platform for the company to engage with the investment community and highlight its growth prospects. Participation in a major investment conference can moderately influence investor sentiment and visibility for Clene Inc.

Clene Inc. reported its second quarter 2025 earnings, which fell short of analysts' expectations. The company's revenue and earnings per share were below forecasts, raising concerns about its financial health and future growth prospects. Clene's management highlighted challenges in product development and market penetration, which contributed to the disappointing results. Investors reacted negatively, leading to a decline in the company's stock price following the announcement. Earnings miss indicates potential challenges in financial performance and market sentiment.

Clene Inc. will present at the Emerging Growth Conference, showcasing its innovative therapies and business strategy to potential investors and stakeholders. The conference aims to connect emerging growth companies with investors, providing a platform for Clene to highlight its advancements and future plans. Participation in the conference may enhance investor awareness and sentiment but is not expected to significantly alter the company's trajectory.

Clene Inc. will present at the Canaccord 45th Annual Growth Conference, showcasing its innovative therapies and strategic vision to investors and industry stakeholders. The presentation aims to highlight the company's advancements and future plans in the biotechnology sector, potentially attracting interest and investment. Participation in a significant investor conference can enhance visibility and market sentiment, impacting investor interest and potential funding.

Clene Inc. provided a regulatory update following a constructive FDA Type C meeting regarding its neurofilament biomarker analysis plan for ALS. The FDA supported Clene's statistical analysis plan for comparing neurofilament light (NfL) biomarker data from its NIH-sponsored Expanded Access Program. Two additional FDA meetings are scheduled for Q3 2025 to discuss ALS survival data and the MS clinical development program. Clene aims to submit a new drug application for ALS under the accelerated approval pathway by the end of 2025, contingent on positive NfL analysis results expected in Q4 2025. The FDA's supportive feedback and upcoming meetings could significantly influence Clene's regulatory strategy and market positioning.

The Q2 Investor Summit presentations are now available for on-demand viewing, featuring insights from various microcap companies, including Clene Inc. (CLNN). Clene is approaching key inflection points with the US FDA in 2025 and plans to file a New Drug Application (NDA) under the accelerated approval pathway in Q4 2025. Clene Inc. is nearing significant regulatory milestones that could greatly influence its market position and investor sentiment.